• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mimedx Group Inc (NQ: MDXG )

    6.870 +0.090 (+1.33%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,351,267
    Open 6.840
    Bid (Size) 6.510 (1)
    Ask (Size) 7.310 (1)
    Prev. Close 6.780
    Today's Range 6.740 - 6.950
    52wk Range 5.570 - 9.270
    Shares Outstanding 111,946,829
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    MDXG Stock Earnings: MiMedx Group Beats EPS, Beats Revenue for Q1 2024
    MDXG stock results show that MiMedx Group beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Mizuho Maintains Buy Rating for MiMedx Group: Here's What You Need To Know
    Via Benzinga

    Performance

    YTD
    -12.71%
    -12.71%
    1 Month
    -11.35%
    -11.35%
    3 Month
    -12.26%
    -12.26%
    6 Month
    -23.50%
    -23.50%
    1 Year
    +8.19%
    +8.19%

    More News

    Read More
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Recap: MiMedx Group Q4 Earnings
    Via Benzinga
    Get Rich Quick With These 3 Biotech Stocks to Buy Now
    Via InvestorPlace
    ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation - MDXG
    Via NewMediaWire
    Exposures Product Safety
    MiMedx Group's Earnings: A Preview
    Via Benzinga
    MDXG LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MiMedx Group, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – MDXG
    From Rosen Law Firm
    Via Business Wire
    MIMEDX ALERT: Bragar Eagel & Squire, P.C. is Investigating MiMedx Group, Inc. on Behalf of MiMedx Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
    From Glancy Prongay & Murray LLP
    Via Business Wire
    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
    From Law Offices of Howard G. Smith
    Via Business Wire
    The Law Offices of Frank R. Cruz Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    Rivian Automotive Reports Weak Delivery Figures, Joins JOYY, MiMedx Group And Other Big Stocks Moving Lower On Tuesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Earnings Scheduled For October 30, 2023
    Via Benzinga
    Chipotle, Amazon, Deckers Outdoor, Capital One And Other Stocks Move Higher On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
    From MediWound Ltd.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    MiMedx Targets Profitability with Strategic Realignment, Suspends Knee Osteoarthritis Program Activities
    Via Benzinga
    MiMedx Group (NASDAQ: MDXG) Reports Q1 2023 Financial Results Showing 21.7% Sales Growth
    Via Spotlight Growth
    Veritone, Samsara, Lexicon Pharmaceuticals And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    BioStem Aims To Stay Ahead Of Competition Through Its Unique Processes And Versatile Offerings In Wound Healing
    Via Benzinga
    Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
    Via FinancialNewsMedia
    Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.